Active pharmaceutical ingredients supplier Novadoz Pharmaceuticals reported on Thursday the receipt of the US FDA's approval for its generic versions of Oseltamivir Phosphate Capsules and Dofetilide Capsules.
According to the company, Dofetilide in 125mcg, 250mcg and 500mcg capsules is AB rated to Pfizer's brand Tykosin. Oseltamivir Phosphate in 30mg, 40mg and 75mg capsules is AB rated to Genentech Pharmaceuticals' Tamiflu.
Dofetilide is an antiarrhythmic drug used sustain a normal heart beat in patients with certain heart rhythm disorders of the atrium. It is used to treat atrial fibrillation, or atrial flutter. Combined brand and generic sales for the product exceed USD63.4m.
Oseltamivir Phosphate is used to treat symptoms caused by the flu virus (influenza) including blocked nasal passages, fever/chills, aches and fatigue. Combined sales for brand and generics amount to over USD188m.
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets